Melanoma, Skin cancer
Results
Phase 3
This trial looked at T-VEC and pembrolizumab for people with melanoma skin cancer. It was for people whose melanoma could not be removed with surgery. The full name for T-VEC is talimogene laherparepvec.
People could join the trial between 2016 and 2018. The team published the results in 2022.
Recruitment start: 17 March 2016
Recruitment end: 26 April 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Kevin Harrington
Amgen
Experimental Cancer Medicine Centre (ECMC)
Last reviewed: 01 Jun 2026
CRUK internal database number: 13832
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
